688 reports of this reaction
2.8% of all ESKETAMINE HYDROCHLORIDE reports
#9 most reported adverse reaction
HYPERTENSION is the #9 most commonly reported adverse reaction for ESKETAMINE HYDROCHLORIDE, manufactured by Janssen Pharmaceuticals Inc.. There are 688 FDA adverse event reports linking ESKETAMINE HYDROCHLORIDE to HYPERTENSION. This represents approximately 2.8% of all 24,470 adverse event reports for this drug.
Patients taking ESKETAMINE HYDROCHLORIDE who experience hypertension should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERTENSION is a less commonly reported adverse event for ESKETAMINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to hypertension, the following adverse reactions have been reported for ESKETAMINE HYDROCHLORIDE:
The following drugs have also been linked to hypertension in FDA adverse event reports:
HYPERTENSION has been reported as an adverse event in 688 FDA reports for ESKETAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERTENSION accounts for approximately 2.8% of all adverse event reports for ESKETAMINE HYDROCHLORIDE, making it a notable side effect.
If you experience hypertension while taking ESKETAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.